<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00495898</url>
  </required_header>
  <id_info>
    <org_study_id>CRDDE-001</org_study_id>
    <nct_id>NCT00495898</nct_id>
  </id_info>
  <brief_title>A Study of Diabetic Patients With De Novo Native Coronary Artery Lesions</brief_title>
  <acronym>SCORPIUS</acronym>
  <official_title>A German Multicenter, Randomized, Controlled, Open-Label Study of the Cypher Sirolimus-Eluting Stent in the Treatment of Diabetic Patients With De Novo Native Coronary Artery Lesions</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Cordis Corporation</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Cordis Corporation</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The main objective of this study is to assess the safety and effectiveness of the CYPHER
      sirolimus-eluting stent in maintaining minimum lumen diameter in de novo native coronary
      artery lesions as compared to the uncoated Bx VELOCITY balloon-expandable stent in patients
      with manifest diabetes mellitus. Both stents are mounted on the Raptorâ Rapid Exchange Stent
      Delivery System.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a multicenter (19 sites), prospective, 2 arm randomized study designed to assess the
      safety and effectiveness of the CYPHER sirolimus-eluting stent as compared to the uncoated Bx
      VELOCITY balloon-expandable stent in patients with manifest diabetes mellitus. Patients with
      de novo native coronary artery lesions &lt;= 42 mm in length and &gt;=2.5mm and &lt;=3.5mm in diameter
      (by visual estimate) will be included in the study. A total of 190 patients will be entered
      and randomly allocated to the CYPHERTM sirolimus-eluting stent or the uncoated Bx VELOCITY
      balloon-expandable stent at a 1:1 ratio. Patients will be followed for 12 months
      post-procedure, with all patients having a repeat angiography at 8 months (± 1 month).

      It is anticipated the total duration of the study will be 18 months: 6 months to complete
      patient enrollment and 12 months for follow up.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>November 2002</start_date>
  <completion_date type="Actual">November 2009</completion_date>
  <primary_completion_date type="Actual">May 2005</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>angiographic in-segment late loss</measure>
    <time_frame>8 months post-procedure</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>late loss</measure>
    <time_frame>8 months post-procedure</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>angiographic binary restenosis</measure>
    <time_frame>8 months post-procedure</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>target lesion revascularization (TLR)</measure>
    <time_frame>8 months post-procedure</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>target vessel revascularization (TVR)</measure>
    <time_frame>8 months post-procedure</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>target vessel failure (TVF)</measure>
    <time_frame>8 months post-procedure</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>procedure success</measure>
    <time_frame>8 months post-procedure</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>lesion success rate</measure>
    <time_frame>0</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>resource use</measure>
    <time_frame>1 year post-procedure</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>productivity loss</measure>
    <time_frame>1 year post-procedure</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Major Adverse Cardiac Events (MACE)</measure>
    <time_frame>30 days, and 8 and 12 months.</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">200</enrollment>
  <condition>Coronary Artery Disease</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>CYPHER sirolimus-eluting stent</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>uncoated Bx VELOCITY balloon-expandable stent</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>CYPHER sirolimus-eluting stent</intervention_name>
    <description>drug-eluting stent</description>
    <arm_group_label>1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>uncoated Bx VELOCITY balloon-expandable stent</intervention_name>
    <description>bare metal stent</description>
    <arm_group_label>2</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Diagnosis of angina pectoris as defined by Canadian Cardiovascular Society
             Classification (CCS I, II, III, IV) OR unstable angina pectoris (Braunwald
             Classification B I-II) OR patients with documented silent ischemia;

          -  Manifest diabetes mellitus, proven by fasting glucose (12 h) &gt; 127 mg/dl or oral
             glucose challenge: &gt;= 200 mg/dl after 2 h or diabetes mellitus already treated with
             oral antidiabetics or insulin;

          -  Treatment of a de novo native coronary artery lesion in a major coronary artery in
             patients with single or multi-vessel disease; patients with 2- or more-vessel-disease
             can be enrolled if previous treatment(s) of those lesions other than the target lesion
             have taken place at least 3 months prior to the enrolment to this study. If more than
             1 study stent is necessary to treat the lesion, overlapping is strongly recommended;

          -  Target vessel diameter at the lesion site is &gt;= 2.5mm and &lt;= 3.5mm (visual estimate);
             (stents will be available in 2.5 / 3.0 mm width);

          -  Target lesion is &lt;= 42mm in length (visual estimate); (stents will be available in 8,
             18 and 33 mm length);

          -  Target lesion diameter stenosis is &gt; 50% and &lt;100% (visual estimate);

        Exclusion Criteria:
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Dietrich Baumgart, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Universität Duisburg-Essen</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Essen</name>
      <address>
        <city>Essen</city>
        <zip>45147</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <results_reference>
    <citation>Baumgart D, Klauss V, Baer F, Hartmann F, Drexler H, Motz W, Klues H, Hofmann S, Völker W, Pfannebecker T, Stoll HP, Nickenig G; SCORPIUS Study Investigators. One-year results of the SCORPIUS study: a German multicenter investigation on the effectiveness of sirolimus-eluting stents in diabetic patients. J Am Coll Cardiol. 2007 Oct 23;50(17):1627-34.</citation>
    <PMID>17950142</PMID>
  </results_reference>
  <verification_date>December 2009</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 2, 2007</study_first_submitted>
  <study_first_submitted_qc>July 2, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 3, 2007</study_first_posted>
  <last_update_submitted>December 2, 2009</last_update_submitted>
  <last_update_submitted_qc>December 2, 2009</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 3, 2009</last_update_posted>
  <responsible_party>
    <name_title>Dr. Hans-Peter Stoll</name_title>
    <organization>Cordis</organization>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Coronary Artery Disease</mesh_term>
    <mesh_term>Myocardial Ischemia</mesh_term>
    <mesh_term>Coronary Disease</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Sirolimus</mesh_term>
    <mesh_term>Everolimus</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

